妇科恶性肿瘤盆腔廓清术后的并发症与复发:COREPEX 研究的生存分析
这项回顾性、多中心、国际研究纳入 2005 年 1 月至 2023 年 3 月间因宫颈、阴道、外阴或子宫内膜癌行前盆腔或全盆腔廓清术的 862 例患者,主要终点为 5 年无病生存。多变量分析识别出全盆腔廓清术、手术切缘阳性、淋巴血管间隙浸润与更差无病生存独立相关,并据此建立预后评分,将患者分为 5 年无病生存 43.7%、24.9%、22.2%、8.0% 的四组。
要点
- 862 例患者中手术切缘肿瘤阴性 676 例(78.4%)。
- 全盆腔廓清术、切缘阳性、淋巴血管间隙浸润与更差无病生存独立相关。
- 预后评分四组 5 年无病生存分别为 43.7%、24.9%、22.2%、8.0%(P<.001)。
核心结论
- 研究识别出与更差无病生存和总生存独立相关的因素以及复发和死亡风险更高的患者亚组。
- 建立了多变量预后评分,可用于患者咨询、监测策略及未来前瞻性研究。
研究设计与样本
- 回顾性、多中心、国际研究,在国家级妇科肿瘤三级转诊中心开展。
- 纳入宫颈、阴道、外阴或子宫内膜癌,2005 年 1 月至 2023 年 3 月间行前盆腔或全盆腔廓清术,治愈或姑息意图,伴或不伴侧方扩展的盆腔内或盆腔切除。
- 排除仅行后盆腔廓清术或未行术前 CT、PET-CT 或 PET 的患者。
- 共纳入 862 例患者,预后评分基于多变量分析建立。
主要发现
- 手术切缘肿瘤阴性 676 例(78.4%)。
- 治愈意图患者中,全盆腔廓清术、手术切缘阳性、淋巴血管间隙浸润与更差无病生存独立相关,行淋巴结清扫与更好无病生存相关。
- 全盆腔廓清术、手术切缘阳性、淋巴血管间隙浸润与总生存下降独立相关,持续性疾病(而非复发性疾病)时行盆腔廓清术对总生存有负面影响。
- 预后评分四组 5 年无病生存分别为 43.7%、24.9%、22.2%、8.0%(P<.001),5 年总生存分别为 54.3%、40.4%、24.0%、4.3%(P<.001)。
- 复发最常见部位为远处,166 例(32.1%);腹主动脉旁淋巴结转移患者 5 年无病生存和癌症特异性生存显著差于仅盆腔转移淋巴结或淋巴结阴性患者(P=.002 和 P<.001)。
关键数值与推荐
- 预后评分四组 5 年无病生存:43.7%、24.9%、22.2%、8.0%(P<.001)。
- 预后评分四组 5 年总生存:54.3%、40.4%、24.0%、4.3%(P<.001)。
- 腹主动脉旁淋巴结转移 vs 仅盆腔转移淋巴结或淋巴结阴性:5 年无病生存 P=.002,癌症特异性生存 P<.001。
- 手术切缘肿瘤阴性 676/862 例(78.4%)。
- 远处复发 166 例(32.1%)。
临床怎么用
- 多变量预后评分可用于患者咨询和监测策略。
- 多变量预后评分可用于未来前瞻性研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To collect data from patients undergoing pelvic exenteration in recent clinical practice. The primary aim was 5-year disease-free survival. Secondary aims were 5-year overall survival, patterns of recurrence, identification of subgroups at higher risk of recurrence and death, survival associated with lymph node metastasis, and development of a prognostic score. METHODS: This was a retrospective, multicenter, international study conducted in tertiary national gynecologic oncology referral centers. Inclusion criteria included cervical, vaginal, vulvar, or endometrial cancer; anterior or total pelvic exenteration performed between January 2005 and March 2023; curative or palliative intent; and with or without laterally extended endopelvic or pelvic resection. Patients were excluded if they underwent posterior pelvic exenteration only or if preoperative computed tomography (CT), positron emission tomography (PET)-CT, or PET was not performed. A prognostic score was developed that was based on multivariable analysis. RESULTS: Eight hundred sixty-two patients were included. Surgical margins were tumor free in 676 (78.4%). In patients treated with curative intent, total pelvic exenteration, positive surgical margins, and presence of lymphovascular space invasion were independently associated with worse disease-free survival. Performance of lymphadenectomy was associated with better disease-free survival. Total pelvic exenteration, positive surgical margins, and presence of lymphovascular space invasion were factors independently associated with decreased overall survival. Performing pelvic exenteration at time of persistent (instead of recurrent) disease negatively affected overall survival. Prognostic score identified four risk groups with a 5-year disease-free survival of 43.7%, 24.9%, 22.2%, and 8.0% ( P <.001). The 5-year overall survival in the four risk groups was 54.3%, 40.4%, 24.0%, and 4.3% ( P <.001). The most frequent sites of recurrence were distant in 166 patients (32.1%). The 5-year disease-free survival and cancer-specific survival in patients with para-aortic lymph node metastasis were significantly worse compared with those in patients with pelvic-only metastatic nodes or with negative nodes ( P =.002 and P <.001, respectively). CONCLUSION: Independent factors associated with worse disease-free survival and overall survival and subgroups of patients at higher risk of recurrence and death were identified. A multivariable prognostic score was developed that can be used for patient counseling and surveillance strategies and for future prospective studies.
引用
- Bizzarri N, Querleu D, Ricotta G, et al. Complications and Recurrence After Pelvic Exenteration for Gynecologic Malignancies: Survival Analysis From the COREPEX Study. Obstet Gynecol. 2025. PMID: 40934517. doi:10.1097/AOG.0000000000006051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。